Galectin Therapeutics Inc [NASDAQ: GALT] jumped around 0.9 points on Tuesday, while shares priced at $2.39 at the close of the session, up 60.40%.
Compared to the average trading volume of 212.87K shares, GALT reached a trading volume of 11536346 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Galectin Therapeutics Inc [GALT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GALT shares is $6.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GALT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Galectin Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 17, 2025. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $9 to $12. The new note on the price target was released on August 13, 2020, representing the official price target for Galectin Therapeutics Inc stock. Previously, the target price had yet another raise to $11, while B. Riley FBR analysts kept a Buy rating on GALT stock. On December 07, 2017, analysts increased their price target for GALT shares from 6 to 10.
How has GALT stock performed recently?
Galectin Therapeutics Inc [GALT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 78.36. With this latest performance, GALT shares gained by 86.72% in over the last four-week period, additionally plugging by 20.10% over the last 6 months – not to mention a drop of -10.15% in the past year of trading.
#####
Galectin Therapeutics Inc [GALT]: Deeper insight into the fundamentals
Galectin Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.08 and a Current Ratio set at 0.08.
Earnings analysis for Galectin Therapeutics Inc [GALT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GALT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Galectin Therapeutics Inc go to 5.57%.
Insider trade positions for Galectin Therapeutics Inc [GALT]
The top three institutional holders of GALT stocks are: VANGUARD GROUP INC with ownership of 2.12 million shares, which is approximately 3.4002%. BLACKROCK INC., holding 1.56 million shares of the stock with an approximate value of $$3.53 million in GALT stocks shares; and BLACKROCK INC., currently with $$2.54 million in GALT stock with ownership which is approximately 1.8093%.
